SR One leads the $37.5m B round for the gene therapy company with existing corporate investor MedImmune Ventures also investing.
Applied Genetic Technologies Corp. (AGTC), a US-based biotechnology company that receives much of its technology licenced from the University of Florida, has raised a $37.5m series B round.
GlaxoSmithKline’s venture unit SR One led the round along with life science venture firm Alta Partners. They were joined by new investor Osage University Partners, a venture fund that invests in university start-ups. Also joining the round were MedImmune Ventures, a corporate venturing unit of AstraZeneca, and existing ventureinvestors Intersouth Partners, and…
